April 20 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES APPOINTMENT OF GENE MACK AS CHIEF FINANCIAL OFFICER & TREASURER.SELLAS LIFE SCIENCES GROUP INC - INTERIM CHIEF FINANCIAL OFFICER ALEKSEY KRYLOV WILL REMAIN WITH SELLAS UNTIL JULY 15.SELLAS LIFE SCIENCES GROUP INC - MACK MOST RECENTLY SERVED AS A CONSULTING CFO, MOST RECENTLY WITH NICOX, SA.
Full Article
April 2 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES GROUP FILES FOR NON-TIMELY 10-K WITH U.S. SEC.
Full Article
April 2 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES POSITIVE INTERIM DATA FROM PHASE 2B NEUVAX™ (NELIPEPIMUT-S) CLINICAL TRIAL IN COMBINATION WITH HERCEPTIN® IN HER2 1+/2+ BREAST CANCER PATIENTS.CLINICALLY AND STATISTICALLY SIGNIFICANT EFFICACY IN TRIPLE NEGATIVE BREAST CANCER.CLINICALLY MEANINGFUL AND STATISTICALLY SIGNIFICANT DIFFERENCE WAS FOUND BETWEEN TWO ARMS IN COHORT OF PATIENTS.ADDITION OF NEUVAX TO HERCEPTIN DID NOT RESULT IN ANY ADDITIONAL CARDIOTOXICITY COMPARED TO HERCEPTIN ALONE.TOLERATED.SPECIFIED INTERIM ANALYSIS SHOWED AN ADVERSE EVENT PROFILE WITH NO NOTABLE DIFFERENCES BETWEEN TREATMENT ARMS.DSMB RECOMMENDED TO SEEK REGULATORY GUIDANCE BY FDA FOR FURTHER DEVELOPMENT OF COMBINATION OF NEUVAX + HERCEPTIN IN TNBC.
Full Article
March 7 (Reuters) - Sellas Life Sciences Group Inc ::SELLAS LIFE SCIENCES ANNOUNCES $10,700,000 PRIVATE PLACEMENT.SELLAS LIFE SCIENCES - FINANCING WILL SUPPORT ADVANCEMENT OF LATE-STAGE IMMUNO-ONCOLOGY PIPELINE.
Full Article
Nov 9 (Reuters) - Galena Biopharma Inc :Galena Biopharma reports third quarter 2017 financial results.Q3 loss per share $0.15 from continuing operations.Galena Biopharma Inc - cash and cash equivalents of approximately $12.9 million as of September 30, 2017, compared with $18.1 million as of December 31, 2016.
Full Article
Oct 19 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc says on October 12, co and Cardinal Health entered into a settlement relating to product swap agreement - SEC filing.Galena Biopharma Inc - pursuant to agreement , co, Cardinal agreed to resolve all of their outstanding disputes over a product swap agreement.Galena Biopharma Inc - Cardinal will destroy all of zuplenz oral soluble film that is returned as a result of product swap agreement.Galena Biopharma Inc - product swap agreement with Cardinal will be terminated as of effective date of agreement.
Full Article
Sept 28 (Reuters) - Galena Biopharma Inc :Galena Biopharma Inc announces completion of enrollment in two NeuVax™ (nelipepimut-s) clinical trials in combination with Trastuzumab.Galena Biopharma Inc - look forward to interim results next year for phase 2b trial and primary endpoints for both trials in 2019.Galena Biopharma Inc - recommendation from dsmb was to continue her2 3+ trial unmodified..
Full Article
Sept 11 (Reuters) - Galena Biopharma Inc ::Galena Biopharma-on Sept 5, unit of co and Biovascular, entered amendment of exclusive license agreement between MPI and BVI dated December 20, 2013.Galena Biopharma - pursuant to amendment parties agreed to resolve outstanding disputes over license agreement, to modify certain terms of agreement.Galena Biopharma- amendment to eliminate 3pct royalty rate on annual net sales of $50 million, 4pct royalty now applies to annual net sales of up to $100 million.
Full Article
Sept 11 (Reuters) - Galena Biopharma Inc ::Galena Biopharma and Biovascular Inc reaffirm GALE-401 partnership.Galena Biopharma-working in conjunction with Sellas Life Sciences, co's proposed merger candidate, Biovascular has withdrawn its notice of termination.Galena - Co, Biovascular amended license agreement to advance asset either through internal clinical development or by seeking licensing partner.Galena Biopharma Inc - co has completed majority of work for initiation of a phase 3 trial in patients with essential thrombocythemia.
Full Article
Sept 8 (Reuters) - Department of Justice: :Department of Justice says "Galena Biopharma Inc to pay more than $7.55 million to resolve alleged false claims related to opioid drug".Settlement resolves lawsuit filed by relator Lynne Dougherty; as part of Sept. 8 resolution, Dougherty will receive over $1.2 million.
Full Article
Earnings vs. 
Estimates